Baseline patient characteristics
tumors, unresectable stage III non‐small‐cell lung cancer
ONCOLOGY, TUMORS, STAGE III NSCLC
We identified 234 patients with stage III NSCLC; 126 received definitive concurrent chemoradiotherapy and were included for further analysis. Baseline characteristics are summarized in Table Baseline patient characteristics for those with unresectable stage III non‐small‐cell lung cancer who proceeded with definitive chemoradiotherapy, including baseline characteristics of patients from the PACIFIC study, derived from Antonia et al.Abbreviations: ECOG, Eastern Cooperative Oncology Group; NA, not applicable; PD‐L1, Programmed death‐ligand 1.
Most patients were male (62%) and current or former smokers (90%) with a median age of 69 years (range 49–85 years). ECOG performance status was 0–1 in 99% of patients. Most tumors were non‐squamous histology (62%) with no driver mutation (86%). Seven patients with EGFR mutations were included in both the eligible (10%) and ineligible (13%) cohorts. Four patients had induction chemotherapy. All patients received platinum doublet chemotherapy concurrently with radiotherapy. Recommended dose radiotherapy was delivered in 90% of patients.Fifty‐eight patients (46%) received durvalumab treatment. Forty‐nine (84%) of these patients completed 12 months of treatment. The mean time to commence durvalumab following radiotherapy completion was 53 days (interquartile range 39–61 days).